J
Joyce Steinberg
Researcher at Astellas Pharma
Publications - 51
Citations - 1522
Joyce Steinberg is an academic researcher from Astellas Pharma. The author has contributed to research in topics: Enzalutamide & Breast cancer. The author has an hindex of 14, co-authored 51 publications receiving 1034 citations. Previous affiliations of Joyce Steinberg include Center for Global Development.
Papers
More filters
Journal ArticleDOI
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Tiffany A. Traina,Tiffany A. Traina,Kathy D. Miller,Denise A. Yardley,Janice F. Eakle,Lee S. Schwartzberg,Joyce O'Shaughnessy,William J. Gradishar,Peter Schmid,Eric P. Winer,Catherine M. Kelly,Rita Nanda,Ayca Gucalp,Ahmad Awada,Laura García-Estévez,Maureen E. Trudeau,Joyce Steinberg,Hirdesh Uppal,Iulia Cristina Tudor,Amy C. Peterson,Javier Cortes +20 more
TL;DR: This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC and demonstrated clinical activity and was well tolerated in Patients with advanced AR- positive TNBC.
Journal ArticleDOI
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg,Karim Fizazi,Fred Saad,N. Shore,Ugo De Giorgi,David F. Penson,Ubirajara Ferreira,Eleni Efstathiou,Katarzyna Madziarska,Michael Kolinsky,Daniel I.G. Cubero,Bettina Noerby,Fabian Zohren,Xun Lin,Katharina Modelska,Jennifer Sugg,Joyce Steinberg,Maha Hussain +17 more
TL;DR: Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgens-depRIvation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level.
Journal ArticleDOI
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).
Tiffany A. Traina,Kathy D. Miller,Denise A. Yardley,Joyce A. O'Shaughnessy,Javier Cortes,Ahmad Awada,Catherine M. Kelly,Maureen E. Trudeau,Peter Schmid,Luca Gianni,Laura García-Estévez,Rita Nanda,Foluso O. Ademuyiwa,Stephen Y. Chan,Joyce Steinberg,Martha Elizabeth Blaney,Iulia Cristina Tudor,Hirdesh Uppal,Amy C. Peterson,Clifford A. Hudis +19 more
TL;DR: The primary endpoint was clinical benefit (CR, PR or SD) at 16 wks (CBR16) in ‘Evaluable’ pts defined as having both AR IHC ≥10% and a response assessment.
Journal ArticleDOI
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y. Yu,Evan Y. Yu,Daniel P. Petrylak,Peter H. O'Donnell,Jae-Lyun Lee,Jae-Lyun Lee,Michiel S. van der Heijden,Yohann Loriot,Mark N. Stein,Andrea Necchi,Takahiro Kojima,Michael R. Harrison,Se Hoon Park,David I. Quinn,Elisabeth I. Heath,Jonathan E. Rosenberg,Joyce Steinberg,Shang-Ying Liang,Janet Trowbridge,Mary Campbell,Bradley Alexander McGregor,Arjun Vasant Balar +21 more
TL;DR: Enfortumab vedotin is an antibody-drug conjugate directed at Nectin-4, a protein highly expressed in urothelial carcinoma as discussed by the authors.
Journal ArticleDOI
Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies
Chiung-Ing Wong,Tong San Koh,Ross A. Soo,Septian Hartono,Choon Hua Thng,Evelyn McKeegan,Wei Peng Yong,Chien-Shing Chen,Soo Chin Lee,John Wong,Robert Lim,Norita Sukri,Siew-Eng Lim,Ai-Bee Ong,Joyce Steinberg,Neeraj Gupta,Rajendra S. Pradhan,Rod A. Humerickhouse,Boon Cher Goh +18 more
TL;DR: ABT-869 by continuous once-daily dosing was tolerable at doses